Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

87.62EUR
29 May 2017
Change (% chg)

-- (--)
Prev Close
€87.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,373,865
52-wk High
€92.97
52-wk Low
€62.50

Select another date:

Mon, May 22 2017

UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr

* Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients

BRIEF-Sanofi receives CHMP recommendation for approval of insulin lispro biosimilar

* REG-SANOFI RECEIVES CHMP RECOMMENDATION FOR APPROVAL OF INSULIN LISPRO BIOSIMILAR

Sanofi says has no "absolute need" to do acquisitions

PARIS Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

Sanofi says has no 'absolute need' to do acquisitions

PARIS Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

UPDATE 1-Sanofi says has no "absolute need" to do acquisitions

PARIS, May 10 Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

Sanofi says has no "absolute need" to do acquisitions

PARIS, May 10 Sanofi is currently looking at several external growth opportunities, after having failed to clinch two large deals recently, but feels it has no urgent need to make acquisitions, the drugmaker's chairman told shareholders on Wednesday.

Sanofi pegs U.S. drug price rises to below healthcare inflation

French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

Select another date:

More From Around the Web